Anocca is a drug and immunotherapy developer aiming to uncover the therapeutic potential of T-cell immunity.
Anocca provides services like biotechnology, immunotherapeutics, drug discovery, drug development, and immunology services.
The company does precise and efficient analysis of T-cell biology, which is required to deliver a variety of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, assisting the life sciences sector in developing a variety of therapies and vaccination strategies.
Anocca was established on October 23, 2014 by Reagan Jarvis in Södertälje, Vasternorrlands Lan.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 21, 2022 | Debt Financing | €25M | 1 | European Investment Bank | — | Detail |
Jul 22, 2021 | Series B | $47M | 5 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
European Investment Bank | Yes | Debt Financing |
Harald Mix | — | Series B |
Nidoco | — | Series B |
Ramsbury Invest AB | — | Series B |
Robert Andreen | — | Series B |
Swedbank Robur’s Ny Teknik | — | Series B |